These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 23394580)

  • 1. MiR-200c and HuR in ovarian cancer.
    Prislei S; Martinelli E; Mariani M; Raspaglio G; Sieber S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
    BMC Cancer; 2013 Feb; 13():72. PubMed ID: 23394580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HuR regulates beta-tubulin isotype expression in ovarian cancer.
    Raspaglio G; De Maria I; Filippetti F; Martinelli E; Zannoni GF; Prislei S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
    Cancer Res; 2010 Jul; 70(14):5891-900. PubMed ID: 20587520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.
    Cittelly DM; Dimitrova I; Howe EN; Cochrane DR; Jean A; Spoelstra NS; Post MD; Lu X; Broaddus RR; Spillman MA; Richer JK
    Mol Cancer Ther; 2012 Dec; 11(12):2556-65. PubMed ID: 23074172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
    Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
    Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
    Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
    Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Xiao F; Li Y; Wan Y; Xue M
    Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
    Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
    Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
    Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S
    J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.
    Balkhi MY; Iwenofu OH; Bakkar N; Ladner KJ; Chandler DS; Houghton PJ; London CA; Kraybill W; Perrotti D; Croce CM; Keller C; Guttridge DC
    Sci Signal; 2013 Jul; 6(286):ra63. PubMed ID: 23901138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
    Denkert C; Weichert W; Pest S; Koch I; Licht D; Köbel M; Reles A; Sehouli J; Dietel M; Hauptmann S
    Cancer Res; 2004 Jan; 64(1):189-95. PubMed ID: 14729623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression.
    Sun DP; Lin CY; Tian YF; Chen LT; Lin LC; Lee SW; Hsing CH; Lee HH; Shiue YL; Huang HY; Li CF; Liang PI
    Tumour Biol; 2013 Oct; 34(5):3059-69. PubMed ID: 23722602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic Role of miR-200c-3p in High-Grade Serous Ovarian Cancer Progression via Targeting the 3'-Untranslated Region of DLC1.
    Ankasha SJ; Shafiee MN; Abdul Wahab N; Raja Ali RA; Mokhtar NM
    Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34071861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
    Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
    Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C.
    Chang TH; Tsai MF; Gow CH; Wu SG; Liu YN; Chang YL; Yu SL; Tsai HC; Lin SW; Chen YW; Kuo PY; Yang PC; Shih JY
    Cancer Lett; 2017 Aug; 402():190-202. PubMed ID: 28610956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
    Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
    Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
    Cao Q; Lu K; Dai S; Hu Y; Fan W
    Int J Clin Exp Pathol; 2014; 7(5):2392-401. PubMed ID: 24966949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
    Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
    Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.